drug · enzyme
avalglucosidase alfa
Phase 3updated 3mo agoby $SNY Sanofi🔗 ChEMBL
Phase 3community read0 votes
Enzyme drug with a maximum clinical stage of Approval (across all indications), with an approval for glycogen storage disease ii and glycogen storage disease due to acid maltase deficiency and 1 investigational indication.
all catalysts(0)
nothing on the calendar yet
Trials studying avalglucosidase alfa
- phase3Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa
- phase4China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD
- —A Global Prospective Observational Registry of Patients With Pompe Disease
- phase2A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa
- —Avalglucosidase Alfa Pregnancy Study
- phase4Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)
- phase3Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease
- phase2Avalglucosidase Alfa Extension Study
News(2)
- STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and moreSanofi is experiencing shortages of two medicines used to treat Pompe disease after the FDA warned the company over manufacturing issuesstat · 7d ago
- STAT+: A shortage of two Sanofi medicines for Pompe disease rattles patientsSanofi is experiencing shortages of two medicines for Pompe disease, alarming patient groups.stat · 8d ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that